Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAACHI GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1467649368
CMS profile
1381570
Location
PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$5,179.40

213 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,938.98 199
Long term medical supply or device loan $1,065.44 12
Education $174.98 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $1,215.81 26
Janssen Biotech, Inc. $518.36 29
AstraZeneca Pharmaceuticals LP $310.75 11
ABBVIE INC. $282.32 12
PFIZER INC. $266.10 12
Merck Sharp & Dohme LLC $244.83 14
Celgene Corporation $240.62 14
Daiichi Sankyo Inc. $227.29 10
Astellas Pharma US Inc $181.57 6
Eisai Inc. $159.26 6
GlaxoSmithKline, LLC. $154.04 11
Alexion Pharmaceuticals, Inc. $129.53 6
Takeda Pharmaceuticals U.S.A., Inc. $122.99 6
SOBI, INC $94.07 3
Lilly USA, LLC $78.23 3
Blueprint Medicines Corporation $66.67 3
Karyopharm Therapeutics Inc. $55.50 3
EMD Serono, Inc. $46.48 2
Agios Pharmaceuticals, Inc. $45.72 3
Ipsen Biopharmaceuticals, Inc $44.36 2
Adaptive Biotechnologies Corporation $42.84 2
Myriad Genetic Laboratories, Inc. $41.04 2
Bayer Healthcare Pharmaceuticals Inc. $37.67 2
Rigel Pharmaceuticals, Inc. $32.25 1
TerSera Therapeutics LLC $31.27 1
Geron Corporation $31.07 1
SpringWorks Therapeutics, Inc. $30.06 2
Fennec Pharmaceuticals, Inc. $30.00 1
GENZYME CORPORATION $28.59 1
Genentech USA, Inc. $26.26 1
Incyte Corporation $25.00 1
Mirati Therapeutics, Inc. $24.91 1
Deciphera Pharmaceuticals Inc. $24.67 1
SERVIER PHARMACEUTICALS LLC $24.52 1
Pharmacosmos Therapeutics Inc. $23.58 1
Genmab U.S., Inc. $22.79 1
Kite Pharma, Inc. $21.67 1
ADC Therapeutics America, Inc. $21.66 1
ARRAY BIOPHARMA INC $21.36 1
Kyowa Kirin, Inc. $21.17 1
BeiGene USA, Inc. $20.43 1
Gilead Sciences, Inc. $19.89 1
E.R. Squibb & Sons, L.L.C. $19.69 1
Regeneron Healthcare Solutions, Inc. $19.69 1
JAZZ PHARMACEUTICALS INC. $19.15 1
Exelixis Inc. $19.11 1
RECORDATI_RARE_DISEASES_INC. $14.56 1

Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAACHI GUPTA

NPI 1467649368 · CMS profile ID 1381570

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467649368?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAACHI GUPTA, NPI 1467649368, CMS profile ID 1381570. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467649368?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SHAACHI GUPTA, NPI 1467649368, CMS profile ID 1381570. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467649368?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SHAACHI GUPTA, NPI 1467649368, CMS profile ID 1381570, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467649368?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

213 matching records · $5,179.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 213 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 213.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $18.8410/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511365 CMS
ABBVIE INC. $17.1810/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103853673 CMS
Novartis Pharmaceuticals Corporation $83.3310/17/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086907595 CMS
Astellas Pharma US Inc $18.7310/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139411047 CMS
Blueprint Medicines Corporation $21.8010/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147441822 CMS
AstraZeneca Pharmaceuticals LP $20.6510/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105900354 CMS
Lilly USA, LLC $27.6410/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135403990 CMS
Adaptive Biotechnologies Corporation $19.2810/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150260092 CMS
Daiichi Sankyo Inc. $14.2910/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089429191 CMS
Janssen Biotech, Inc. $22.4910/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511248 CMS
Janssen Biotech, Inc. $21.7910/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511435 CMS
Novartis Pharmaceuticals Corporation $83.3309/27/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086907575 CMS
Novartis Pharmaceuticals Corporation $14.2009/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086907591 CMS
PFIZER INC. $22.0809/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131355698 CMS
Janssen Biotech, Inc. $18.4409/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511446 CMS
Myriad Genetic Laboratories, Inc. $18.7709/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152532072 CMS
Genentech USA, Inc. $26.2609/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133110242 CMS
ABBVIE INC. $26.5809/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103853671 CMS
AstraZeneca Pharmaceuticals LP $23.9309/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104383515 CMS
Ipsen Biopharmaceuticals, Inc $21.0309/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091953092 CMS
Merck Sharp & Dohme LLC $13.0109/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141776933 CMS
Exelixis Inc. $19.1109/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138565524 CMS
PFIZER INC. $16.5809/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131367232 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.3109/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086133460 CMS
Alexion Pharmaceuticals, Inc. $16.5909/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093968486 CMS
Daiichi Sankyo Inc. $26.5809/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089429470 CMS
Janssen Biotech, Inc. $24.8609/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511553 CMS
Celgene Corporation $0.7608/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133012 CMS
Celgene Corporation $27.6608/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133014 CMS
Celgene Corporation $19.7608/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133010 CMS
Eisai Inc. $27.8308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110780634 CMS
Daiichi Sankyo Inc. $15.5408/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089429438 CMS
Janssen Biotech, Inc. $19.5208/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511305 CMS
Novartis Pharmaceuticals Corporation $83.3308/23/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086907573 CMS
Novartis Pharmaceuticals Corporation $14.4008/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086907571 CMS
GlaxoSmithKline, LLC. $14.6808/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116564688 CMS
ABBVIE INC. $33.9108/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103853669 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.8808/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144958460 CMS
BeiGene USA, Inc. $20.4308/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120868388 CMS
SOBI, INC $31.4808/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141424423 CMS
SpringWorks Therapeutics, Inc. $16.6308/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085804693 CMS
ABBVIE INC. $33.5308/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103853667 CMS
Kyowa Kirin, Inc. $21.1708/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127042911 CMS
Celgene Corporation $26.1708/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133008 CMS
Eisai Inc. $33.7808/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110780638 CMS
PFIZER INC. $9.9908/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131771653 CMS
AstraZeneca Pharmaceuticals LP $18.5508/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104513014 CMS
AstraZeneca Pharmaceuticals LP $24.8008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105307511 CMS
Deciphera Pharmaceuticals Inc. $24.6707/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145873393 CMS
Janssen Biotech, Inc. $20.0607/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078511685 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,624.73 153
PY2020 $1,143.42 65
PY2021 $1,713.96 102
PY2022 $2,230.30 131
PY2023 $3,359.49 161
PY2024 $5,179.40 213
PY2025 $8,338.26 256

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $102,872.71 44
PY2024 Principal investigator $37,792.96 14
PY2023 Principal investigator $131,576.78 93
PY2022 Recipient $1,908.00 1
PY2022 Principal investigator $113,723.00 68
PY2021 Principal investigator $11,504.47 5
PY2020 Principal investigator $20,000.04 5
PY2019 Recipient $5,846.00 1
PY2019 Principal investigator $51,977.35 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739395
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 12/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743038
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739393
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739391
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743034
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743036
Principal investigator 1 Incyte Corporation $956.00 10/15/2025 Non-covered Recipient Entity
SANSUM CLINIC : SANTA BARBARA
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240584481
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743032
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739363
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739365
Principal investigator 1 Merck Sharp & Dohme LLC $34,811.71 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists - East
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232922948
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742840
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742842
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742844
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742846
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742848
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742850
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739367
Principal investigator 1 Incyte Corporation $956.00 07/15/2025 Non-covered Recipient Entity
SANSUM CLINIC : SANTA BARBARA
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240584477
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739369
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739371
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739373
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739375
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739377
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742834
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742836
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742838
Principal investigator 1 Eli Lilly and Company $1,998.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1187882400
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739379
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739381
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
HONOR HEALTH VIRGINIA G. PIPER CANCER CARE NETWORK
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240538457
Principal investigator 1 Genentech, Inc. $300.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649599
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739383
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739385
Principal investigator 1 Genentech, Inc. $850.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649576
Principal investigator 1 Eli Lilly and Company $2,664.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1187891678
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742830
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742832
Principal investigator 1 Genentech, Inc. $2,575.00 02/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649583
Principal investigator 1 Genentech, Inc. $1,500.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649603
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739387
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739389
Principal investigator 1 Genentech, Inc. $2,000.00 01/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649612
Principal investigator 1 Incyte Corporation $956.00 01/15/2025 Non-covered Recipient Entity
HONOR HEALTH VIRGINIA G. PIPER CANCER CARE NETWORK
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240538452